ETR:MOR MorphoSys (MOR) Stock Price, News & Analysis → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free MOR Stock Alerts €66.65 +0.55 (+0.83%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range€66.00▼€67.0050-Day Range€65.10▼€67.9552-Week Range€14.52▼€68.00Volume72,984 shsAverage Volume153,687 shsMarket Capitalization$2.51 billionP/E RatioN/ADividend Yield1.26%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get MorphoSys alerts: Email Address Ad Allegiance GoldCould Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About MorphoSys Stock (ETR:MOR)MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOR Stock News HeadlinesMay 2, 2024 | finance.yahoo.comUPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billionApril 30, 2024 | seekingalpha.comMorphoSys: Hold Rating Until The Novartis Deal ClosesMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...April 29, 2024 | msn.comGermany stocks mixed at close of trade; DAX down 0.16%April 28, 2024 | msn.comNew safety risk for MorphoSys drug could complicate Novartis deal - STATApril 28, 2024 | markets.businessinsider.comMorphoSys earnings: here's what Wall Street expectsApril 24, 2024 | finance.yahoo.comMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual MeetingApril 11, 2024 | msn.comGerman biopharma MorphoSys recommends Novartis offer be acceptedMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...April 11, 2024 | finanznachrichten.deNovartis Pharma AG: Novartis tender offer for MorphoSys AG commencesApril 11, 2024 | finance.yahoo.comNovartis tender offer for MorphoSys AG commencesApril 11, 2024 | msn.comNovartis commences tender offer for MorphoSysApril 11, 2024 | msn.comNovartis begins tender offer for cancer-focused MorphoSysApril 11, 2024 | finance.yahoo.comUPDATE 2-Novartis begins tender offer for cancer-focused MorphoSysApril 4, 2024 | seekingalpha.comNovartis: Higher Guidance, Now A BuyMarch 22, 2024 | markets.businessinsider.comEQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR ActMarch 15, 2024 | finance.yahoo.comMorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comEQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | benzinga.comMorphoSys: Q4 Earnings InsightsMarch 12, 2024 | msn.comGerman regulators approve Novartis deal to buy drugmaker MorphosysFebruary 15, 2024 | finance.yahoo.comWhat Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?February 8, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & MoreFebruary 7, 2024 | realmoney.thestreet.comMorphoSys just downgraded at JMP Securities, here's whyFebruary 6, 2024 | finance.yahoo.comNovartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology DrugFebruary 6, 2024 | seekingalpha.comNovartis And MorphoSys Are A Perfect MatchFebruary 5, 2024 | finance.yahoo.comNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cashFebruary 5, 2024 | finance.yahoo.comUPDATE 1-Novartis to acquire cancer drug developer MorphoSys for $2.9 blnSee More Headlines Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MOR CUSIPN/A CIKN/A Webwww.morphosys.de Phone+49-89-899270FaxN/AEmployees524Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€5.53) Trailing P/E RatioN/A Forward P/E Ratio327.49 P/E Growth0.06Net Income$-189,730,000.00 Net Margins-79.63% Pretax MarginN/A Return on Equity-183.80% Return on Assets-6.82% Debt Debt-to-Equity Ratio3,454.18 Current Ratio3.08 Quick Ratio3.49 Sales & Book Value Annual Sales$238.28 million Price / Sales10.55 Cash Flow€128.57 per share Price / Cash Flow0.52 Book Value€1.30 per share Price / Book51.27Miscellaneous Outstanding Shares37,720,000Free FloatN/AMarket Cap$2.51 billion OptionableNot Optionable Beta0.60 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 59)Chairman of Management Board, MD & CEO Comp: $1.76MDr. Lucinda Crabtree Ph.D. (Age 45)CFO & Member of Management Board Comp: $705.82kMs. Charlotte Lohmann (Age 54)Chief Legal and Human Resources Officer & Member of Management Board Comp: $474.1kMr. Klaus De WallHead of Accounting & TaxDr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Julia Neugebauer Ph.D.Head of Investor RelationsDr. Barbara Krebs-Pohl Ph.D.Chief Business OfficerDr. Günter WellnhoferHead of Technical OperationsDr. Harald WatzkaHead of Alliance ManagementMs. Yen Ching ChuaHead of Clinical OperationsMore ExecutivesKey CompetitorsBiotest AktiengesellschaftETR:BIOEvotecETR:EVTShop Apotheke EuropeETR:SAEGerresheimerETR:GXICompuGroup Medical SE & Co. KGaAETR:COPView All Competitors MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed in 2024? MorphoSys' stock was trading at €34.00 at the beginning of the year. Since then, MOR stock has increased by 96.0% and is now trading at €66.65. View the best growth stocks for 2024 here. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Novo Nordisk A/S (NVO), Gilead Sciences (GILD), SolarEdge Technologies (SEDG), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Abbott Laboratories (ABT), MercadoLibre (MELI), Neurocrine Biosciences (NBIX), Nightstar Therapeutics (NITE) and NVIDIA (NVDA). This page (ETR:MOR) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.